中药辅助治疗重症肺炎的疗效与安全性证据映射
该研究通过证据映射方法,系统检索中英文数据库至2023年8月,纳入354项随机对照试验和17项系统评价/Meta分析,评估中药辅助治疗重症肺炎的疗效与安全性。结果显示中药联合常规治疗可改善临床总有效率、缩短机械通气时间和住院时间、降低炎症指标等,安全性无显著差异,但原始研究和方法学质量普遍较低。
要点
- 中药联合常规治疗可提高重症肺炎临床总有效率和中医证候疗效。
- 联合治疗可缩短机械通气时间、感染控制时间及住院和ICU时间。
- 不良反应发生率与常规治疗相比无显著差异(p>0.05)。
核心结论
- 中药联合常规治疗在重症肺炎的疗效、临床体征、实验室结果和生活质量结局方面具有优势。
- 与常规治疗相比,联合治疗在安全性结局方面无差异。
- 清金化痰汤是最有前景的靶向方剂,宣白承气汤结论为「可能有益」。
- 血必净注射液和痰热清注射液是治疗重症肺炎的两种常用中药注射剂,两者均「可能有益」。
研究设计与样本
- 证据映射研究,系统检索PubMed、EMBASE、Cochrane Library、Web of Science、CNKI、万方、维普和SinoMed数据库,从建库至2023年8月。
- 纳入关于成人重症肺炎或其并发症中药辅助治疗的随机对照试验、系统评价和Meta分析。
- 共纳入354项随机对照试验和17项系统评价或Meta分析。
- 采用Cochrane ROB工具评估随机对照试验偏倚风险,采用AMSTAR-2、ROBIS工具和GRADE系统评估系统评价/Meta分析的方法学质量、偏倚风险和证据质量。
主要发现
- 已发表的随机对照试验存在设计不合理、样本量有限、对非药物治疗和辨证论治关注不足、结局指标选择或使用不当等缺陷。
- 大多数结局的证据质量被评为「低」。
- 与仅常规治疗相比,中药联合常规治疗可提高临床总有效率和中医证候疗效,缩短机械通气时间、感染控制时间及住院和ICU时间。
- 联合治疗可显著降低体温、呼吸频率、心率、白细胞计数、C反应蛋白、降钙素原、血液炎症因子、细菌学应答和D-二聚体水平,降低CPIS、APACHE II评分和PSI评分,改善肺部影像学特征、动脉血气指标(包括动脉氧分压、动脉血氧饱和度和氧合指数)和肺功能(包括用力肺活量和第一秒用力呼气容积)(p < 0.05)。
关键数值与推荐
- 大多数系统评价/Meta分析得出结论,与仅常规治疗相比,中药联合常规治疗「有益」或「可能有益」。
- 清金化痰汤是最有前景的靶向方剂。
- 宣白承气汤的结论为「可能有益」。
- 血必净注射液和痰热清注射液均「可能有益」。
临床怎么用
- 临床可考虑在常规治疗基础上联合中药辅助治疗重症肺炎,以改善疗效和临床指标。
- 清金化痰汤、宣白承气汤、血必净注射液和痰热清注射液可作为有前景的选择。
- 联合治疗未增加不良反应风险,但需注意原始研究质量较低,应用时结合临床实际。
局限性
- 已发表的随机对照试验存在设计不合理、样本量有限、对非药物治疗和辨证论治关注不足、结局指标选择或使用不当等缺陷。
- 大多数结局的证据质量被评为「低」。
- 未来需要多中心、大样本、高方法学质量的随机对照试验,并提高系统评价/Meta分析的方法学设计和质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Objective: Severe pneumonia is a critical respiratory disease with high mortality. There is insufficient evidence on the efficacy and safety of traditional Chinese medicine (TCM) adjuvant therapy for severe pneumonia. This study aims to identify, describe, assess, and summarize the currently available high-quality design evidence on TCM adjuvant therapy for severe pneumonia to identify evidence gaps using the evidence mapping approach. Methods: Systematic searches were performed on English and Chinese online databases (PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, WanFang Data, CQVIP, and SinoMed) to identify papers from inception until August 2023 for inclusion into the review. Randomized controlled trials (RCTs), systematic reviews (SRs), and meta-analyses concerning TCM adjuvant therapy for severe pneumonia or its complications in adults were included. The risk of bias in RCTs was evaluated by using the Cochrane Handbook ROB tool. The Assessment of Multiple Systematic Reviews 2 (AMSTAR-2), the Risk of Bias in Systematic Review (ROBIS) tool, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system were used to assess the methodological quality, risk of bias, and evidence quality of SRs or meta-analyses, respectively. Then, a bubble plot was designed to visually display information in four dimensions. Results: A total of 354 RCTs and 17 SRs or meta-analyses met the inclusion criteria. The published RCTs had several flaws, such as unreasonable design, limited sample size, insufficient attention to non-drug therapy studies and syndrome differentiation, improper selection or use of outcome indicators, and failure to provide high-quality evidence. Sixteen SRs or meta-analyses of methodological quality scored "Critically Low" confidence. Twelve SRs or meta-analyses were rated as "High Risk." Most outcomes were rated as "Low" evidence quality. We found that TCM combined with conventional treatment could improve the clinical total effective rate and the TCM syndromes efficacy. The combined approach could also shorten mechanical ventilation time, infection control time, and length of hospital and ICU stay; significantly reduce temperature, respiratory rate, heart rate, white blood cell counts, levels of C-reactive protein, procalcitonin, blood inflammatory factors, bacteriological response, and D-dimer; decrease CPIS, APACHE II score, and PSI score; improve pulmonary imaging features, arterial blood gas indicators (including arterial oxygen pressure, arterial oxygen saturation, and oxygen index), and lung function (including forced vital capacity and forced expiratory volume in the first second) for severe pneumonia compared with conventional treatment only (p < 0.05). There was no significant difference in adverse reactions and incidence of adverse events (p > 0.05). In addition, compared with conventional treatment only, most SRs or meta-analyses concluded that TCM combined with conventional treatment was "Beneficial" or "Probably beneficial." Conclusion: TCM combined with conventional treatment had advantages in efficacy, clinical signs, laboratory results, and life quality outcomes of severe pneumonia, with no difference in safety outcomes compared with conventional treatment only. QingJin Huatan decoction is the most promising target, and Xuanbai Chengqi decoction has a "Probably beneficial" conclusion. XueBiJing injection and TanReQing injection are two commonly used Chinese herbal injections for treating severe pneumonia, and both are "Probably beneficial." However, there was a need for multicenter RCTs with large sample sizes and high methodological quality in the future. In addition, the methodological design and quality of SRs or meta-analyses should be improved to form high-quality, evidence-based medical evidence and provide evidence for the effectiveness and safety of TCM adjuvant therapy for severe pneumonia.
引用
- Xie K, Guan S, Jing H, et al. Efficacy and safety of traditional Chinese medicine adjuvant therapy for severe pneumonia: evidence mapping of the randomized controlled trials, systematic reviews, and meta-analyses. Front Pharmacol. 2023. PMID: 37841930. doi:10.3389/fphar.2023.1227436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。